Tufts Center for the Study of Drug Development’s Post

🚀 Countdown to Transformation Just walked into Ionis Pharmaceuticals' HQ in Carlsbad, and the energy is ELECTRIC! The digital countdown clock ticking down to December 19 is hard to miss. 🎯 FDA's decision could change everything. Ionis is on the brink of approval for olezarsen, a therapy to improve fat breakdown in our bodies. Initially, it targets a rare genetic disease, familial chylomicronemia syndrome, but it has the potential to help many more people with high triglycerides. Projected peak sales? $2 billion by 2035, according to Wolfe Research! 💥 This isn't just another approval. This could be a game-changer. Could olezarsen be the next big thing in treating high triglycerides? #Biotech #FDAApproval #HealthInnovation

🧬💊 23andMe is stepping into the world of drug discovery, aiming to transform genetic insights into groundbreaking therapies! What does this mean for the future of medicine? Read more about their journey from DNA kits to potential cures. #Genetics #Biotech #DrugDiscovery #HealthcareInnovation #23andMe #FutureOfMedicine https://lnkd.in/etE22jiA

#Hello connections🙋 🎉"💫Excited to share my latest achievement: completing a comprehensive review paper on """METHYLATION RISK SCORE AS A PREDICTIVE PARAMETER FOR DISEASE VULNERABILITY " in the " WORLD JOURNAL OF PHARMACEUTICAL RESEARCH """ Can find the paper on link 🔗https://lnkd.in/gmqb3aJc Inciting the comprehensive overview of the current understanding of DNA methylation dynamics, encompassing its mechanisms, regulation, and functional implications. Highlighting their methodologies, applications and methylation associated with multiple diseases. Genetic risk scores (GRS) are extensively used for risk prediction as well as in association and interaction studies. Review serves as a comprehensive guide for researchers and clinicians alike, illuminating the current landscape of MRS research and charting future directions towards their clinical implementation and impact on patient care. #published #journal #review paper #publication #academic #achievement

Thoughts on this? >> Q&A: Lilly’s top scientists on genetic medicine ambitions, and how they’re not just for rare diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #pharma #biotech

Thoughts on this? >> Q&A: Lilly’s top scientists on genetic medicine ambitions, and how they’re not just for rare diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharmaceutical #pharma

In Drug Channels, MMIT and The Dedham Group share five steps pharma companies can take to improve patient access to genetic testing and next-generation sequencing, from educating providers on lab networks to sharing appropriate test requirements and patient eligibility criteria. Read it here: https://ow.ly/TN1N50RFGZ8 #Pharma #PharmaManufacturers #MarketAccess

Enhance your research with Trailhead Biosystem's Custom iPSC Differentiation service. We specialize in converting your iPSCs into the specific cell types required for your projects. Whether for disease modeling, drug screening, or basic research, our tailored approach provides high-quality, physiologically relevant cells to meet your specific needs. For more information on our Custom iPSC Differentiation Service or to discuss your project needs, visit https://lnkd.in/gkEbXXtA #iPSCs #StemCellDifferentiation #CustomCellCulture #Biotechnology #CellBiology #DrugDiscovery #PersonalizedMedicine

Excited to moderate an impactful discussion on October 10th about the horizon for RNA-based therapies in the US. With help from sponsors, #Avalere is hosting an esteemed panel of drug development, clinical, and policymaker voices. They will discuss how to make sense of these complex medicines, their promise, and how we can realize their positive impacts for patients. Register at the link! #RNA #GTT #RNAi #IRA #DrugDevelopment #Innovation

I just expanded my knowledge on "Clinical Applications of Pharmacogenomics from Bench to Bedside" by attending a fascinating webinar organized by #DrOmicsLabs. I learned how pharmacogenomics personalizes medicine for better patient outcomes? and become aware of the evolving role of genetic testing in drug development and treatment decisions. #DrOmicslabs #Biotechnology #Pharmocogenomics #PersonalizedMedicines #DrugDiscovery #DrugEfficacy

Orchard Therapeutics’ ultra-rare disease drug #Lenmeldy is vaulting to the list of most expensive drugs ever with a wholesale acquisition cost of $4.25 million for the one-time treatment in the US.... ....In justifying the price tag, Orchard said that it referenced the Institute for Clinical and Economic Review’s (ICER) assessment, which set the health benefit price benchmark for Lenmeldy at up to $3.94 million.... ...The company added that the price is “reflective of the value the therapy may deliver to eligible patients and their families, as well the potential long-term impact treatment may have on overall healthcare utilization, minimization of productivity loss for caregivers, and life opportunities for patients.”... Bennett Smith Institute for Clinical and Economic Review (ICER) ##onetimetreatment #valueoftherapy #pricing #patientimpact #raredisease #rarediseases #genetherapy #cellandgenetherapy #regenerativemedicine #advancedtherapies #biotech #biotechnology #pharma #pharmaceuticals #lifesciences #healthcare #patientacccess #reimbursement #metachromaticleukodystrophy #MLD #children #ultrararedisease #economicvalue Kyowa Kirin Co., Ltd. #USpricing